Drug Trial Radar · NCT00124436
Follow-up Efficacy and Safety of Alitretinoin in Severe Chronic Hand Dermatitis
Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
300
Actual
Start
Mar 2005
Primary completion
Jan 2007
Study completion Feb 2007
Sponsor
- Lead sponsor
- Basilea PharmaceuticaIndustry
- Sponsor type
- Industry
- First posted
- Jul 28, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Other
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients who have been treated in study protocol BAP089 may have responded to treatment, and subsequently relapsed to \>75% of the baseline disease severity, will be investigated for response to further treatment with alitretinoin. Also, patients who have responded with mild or moderate disease will be investigated for additional treatment effect after prolongated treatment.
Conditions
- Hand Dermatoses
Interventions
alitretinoinDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response of chronic hand dermatitis to study treatment as assessed by Physicians Global Assessment, at week 12 or 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Thomas Ruzicka
Düsseldorf, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.